艾本与骨膦治疗非小细胞肺癌骨转移的疗效比较

Comparison of the Effects of Ibandronate and Bonefos on Non-small Cell Lung Cancer with Bone Metastases

目的:评价国产伊班膦酸钠(艾本)治疗非小细胞肺癌骨转移的临床疗效并探讨安全性。同时与骨膦进行疗效和不良反应的比较,寻找更优的治疗方法。方法:将山东省肿瘤医院2003年11月至2006年11月间86例非小细胞肺癌骨转移患者随机分为两组:艾本组44例和骨膦组42例。艾本应用4mg加入500ml生理盐水中静脉滴注2h,每4周应用1次。骨膦应用300mg加入500ml生理盐水中静脉滴注3h,连用5天后改为口服800mg,2次/日,30天为1个周期。化疗方案均选择以顺铂为基础的两药联合方案。治疗2个疗程结束后观察3个月并评价疗效。结果:两组在止痛、活动能力改善和对骨转移灶的有效率方面进行比较,艾本组有效率分别为81.8%(36/44)、68.2%(30/44)和52.3%(23/44),骨膦组分别为73.8%(31/42)、76.2%(32/42)和45.2%(19/42),两组相比差异无统计学意义(P>0.05)。患者用药后一般情况有所改善。不良反应主要表现为一过性发热、消化道反应、骨髓抑制、乏力、四肢肌肉酸痛等,无治疗相关性死亡。结论:艾本治疗非小细胞肺癌骨转移与骨膦疗效和不良反应相当,应用艾本更为方便快捷。

Objective： To evaluate the clinical efficacy and safety of lbaudronate and Bonefos for non-small cell lung cancer （NSCLC） witb bone metastases. Methods： A total of 86 NSCLC patients with bone metastases were randomly divided into two groups： 44 in the lbandronate group and 42 in the Bonefos group. The chemotherapy in buth groups was Cisplatin-based. The therapeutic efficacy was evaluated after 2 cycles of treatment, with 21 days for each cycle. Results： The response rate of pain relief, improvement in daily living and effective rate on bone metastatic loci was 81.8% （36/44）. 68.2%（30/44） and 52.3%（23/44）, respectively, in the lbandronate group and 73.8%（31/42）, 76.2%（32/42） and 45.2% （19/ 42）, respectively, in the Bonefos group. No significant difference was found between the two groups （P〉0.05）. The side effects could be tolerated. Conclusion： The effects of Ibandronate and Bonefos on NSCLC patients with bone metastases comparable. The administration of Ibandronate is more convenient.